Michele Schiavon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michele Schiavon has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Dalla Man
Department of Information Engineering, University of Padova, Padova, Italy
24 shared publications - Claudio Cobelli
University of Padova, Padova, Italy
10 shared publications - Lia Bally
Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital Bern University Hospital, University of Bern Bern Switzerland
7 shared publications - David Herzig
Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital Bern University Hospital, University of Bern Bern Switzerland
5 shared publications - Edoardo Faggionato
University of Padova
5 shared publications - Roberto Visentin
Department of Information Engineering, University of Padua, Padua, Italy
5 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (11)
Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221
Antisense oligonucleotides are small synthetic DNA or RNA molecules that can be used to modulate gene expression, particularly to block the production of unwanted proteins. This makes them potentially powerful drugs to contrast cancer growth. Drug development is a long process that includes preclinical and clinical studies. Preclinical animal studies are designed to assess drug kinetics and safety before progressing to clinical trials, as they may predict the therapeutic dose to be used in the “first in human” (FIH) studies. This is usually achieved by applying allometric scaling methods that allow predicting the human pharmacokinetic (PK) parameters from those estimated in animals. Selecting the appropriate scaling formula reduces the risk of translational uncertainty and supports the design of FIH studies. The aim of this study is to compare the accuracy of different allometric scaling methods in predicting human PK of the antisense oligonucleotide LNA‐i‐miR‐221, a powerful inhibitor of microRNA miR‐221, which was found to be deregulated in several malignancies, favoring cancer progression. To do that, we exploited the availability of PK data of the drug in both Sprague Dawley rats and humans and we found that the best scaling method for both clearance and distribution volume is the simple allometry, with predictions laying within the 2‐fold and 4‐fold error interval, respectively. This study contributes to identifying the most accurate scaling methods among the evaluated single‐species approaches to extrapolate human pharmacokinetic for LNA‐i‐miR‐221, possibly offering a starting point for future studies involving antisense oligonucleotides.
- 5 November 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (11)
Open AccessAssessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221
Antisense oligonucleotides are small synthetic DNA or RNA molecules that can be used to modulate gene expression, particularly to block the production of unwanted proteins. This makes them potentially powerful drugs to contrast cancer growth. Drug development is a long process that includes preclinical and clinical studies. Preclinical animal studies are designed to assess drug kinetics and safety before progressing to clinical trials, as they may predict the therapeutic dose to be used in the “first in human” (FIH) studies. This is usually achieved by applying allometric scaling methods that allow predicting the human pharmacokinetic (PK) parameters from those estimated in animals. Selecting the appropriate scaling formula reduces the risk of translational uncertainty and supports the design of FIH studies. The aim of this study is to compare the accuracy of different allometric scaling methods in predicting human PK of the antisense oligonucleotide LNA‐i‐miR‐221, a powerful inhibitor of microRNA miR‐221, which was found to be deregulated in several malignancies, favoring cancer progression. To do that, we exploited the availability of PK data of the drug in both Sprague Dawley rats and humans and we found that the best scaling method for both clearance and distribution volume is the simple allometry, with predictions laying within the 2‐fold and 4‐fold error interval, respectively. This study contributes to identifying the most accurate scaling methods among the evaluated single‐species approaches to extrapolate human pharmacokinetic for LNA‐i‐miR‐221, possibly offering a starting point for future studies involving antisense oligonucleotides.
- Open Access
- 30 October 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 289
Nonlinear mixed-effects modeling of gastrointestinal glucose absorption for Bayesian digital twin identification
- 30 October 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 289
Open AccessNonlinear mixed-effects modeling of gastrointestinal glucose absorption for Bayesian digital twin identification
- Open Access
- 26 October 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 288
Gluclas 2.0 — A mobile app for clinical decision support during glucose clamps
- 26 October 2026
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 288
Open AccessGluclas 2.0 — A mobile app for clinical decision support during glucose clamps
- 24 April 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Quantifying the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Background: Quantifying the effect of meal composition (MC) on postprandial glucose excursions would allow optimizing insulin therapy, accounting for fat and protein that can affect gastric retention (GR), glucose rate of appearance (R a ), and insulin sensitivity (S I ). Such variables can be estimated from continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) data using the Minimally-Invasive Oral Minimal Model (MI-OMM). In this work, we aim to quantify the effect of MC on those variables by applying the MI-OMM on a data set of prandial CGM and CSII profiles where MC information was available. Methods: A total of 120 individuals with type 1 diabetes (age = 15.5 ± 11.5 years, weight = 51.3 ± 28.0 kg) were monitored under free-living conditions while using CGM and CSII, and MC was carefully recorded. We extracted 353 CGM and CSII traces using predefined criteria and classified them into low or high fat content and low or high protein content. Finally, the MI-OMM was used to estimate GR, R a , and S I in each meal. Results: MI-OMM was able to fit CGM profiles and provided precise and physiologically plausible parameter estimates. Comparison among different classes of meals showed that a high content of fat and protein in the meal significantly slowed both GR ( P < .01) and R a ( P < .01), and reduced S I ( P < .05). Conclusions: In this work, the effect of MC on postprandial glucose excursion was quantified in real-life conditions with the help of a model-based methodology. These results are usable for redesigning current insulin therapies, accounting for the presence of fat and protein in meals.
- 24 April 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Quantifying the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Background: Quantifying the effect of meal composition (MC) on postprandial glucose excursions would allow optimizing insulin therapy, accounting for fat and protein that can affect gastric retention (GR), glucose rate of appearance (R a ), and insulin sensitivity (S I ). Such variables can be estimated from continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) data using the Minimally-Invasive Oral Minimal Model (MI-OMM). In this work, we aim to quantify the effect of MC on those variables by applying the MI-OMM on a data set of prandial CGM and CSII profiles where MC information was available. Methods: A total of 120 individuals with type 1 diabetes (age = 15.5 ± 11.5 years, weight = 51.3 ± 28.0 kg) were monitored under free-living conditions while using CGM and CSII, and MC was carefully recorded. We extracted 353 CGM and CSII traces using predefined criteria and classified them into low or high fat content and low or high protein content. Finally, the MI-OMM was used to estimate GR, R a , and S I in each meal. Results: MI-OMM was able to fit CGM profiles and provided precise and physiologically plausible parameter estimates. Comparison among different classes of meals showed that a high content of fat and protein in the meal significantly slowed both GR ( P < .01) and R a ( P < .01), and reduced S I ( P < .05). Conclusions: In this work, the effect of MC on postprandial glucose excursion was quantified in real-life conditions with the help of a model-based methodology. These results are usable for redesigning current insulin therapies, accounting for the presence of fat and protein in meals.
- 20 November 2025
- Published by American Diabetes Association in Diabetes
- Vol. 75 (2) , 256-263
Postprandial Glucagon Metabolism in Healthy and Type 1 Diabetes
Early postprandial glucagon concentrations are higher in type 1 diabetes (T1D) than in individuals with no diabetes (ND). To determine the cause, we infused stable [13C9, 15N1]glucagon before, during, and after a mixed meal in 16 ND and 16 T1D individuals to measure glucagon turnover. In a subcohort of 9 ND and 12 T1D individuals, we estimated [13C9, 15N1]glucagon kinetics during steady state. A linear, single-compartment model described [13C9, 15N1]glucagon kinetics and allowed precise estimation of the volume of distribution (VD) and clearance rate (CL). Model parameters were similar between groups, with the VD of [13C9, 15N1]glucagon at 42.1 ± 3.3 mL/kg, implying that [13C9, 15N1]glucagon distributes in a single compartment and with VD approximating the plasma volume and CL at 10.6 ± 0.9 mL/kg/min. Higher early (0–120 min after meal ingestion) postprandial glucagon concentrations (1,907.9 ± 373.4 vs. −93.6 ± 240.5 pg/mL · 120 min P < 0.001) observed in T1D was due to higher rates of glucagon appearance (3.39 ± 2.8 vs. −3.95 ± 2.0 ng/kg · 120 min, P < 0.04) and disappearance (2.13 ± 2.6 vs. −5.28 ± 2.1 ng/kg · 120 min, P < 0.04) compared with ND. We have determined postprandial glucagon turnover in humans and have demonstrated that changes in postprandial glucagon concentrations in T1D are due to increased rates of glucagon turnover during the early postprandial period. Article Highlights: This study was conducted to determine postprandial glucagon metabolism in people with and without type 1 diabetes. We wanted to determine the cause for higher early postprandial glucagon concentrations in type 1 diabetes. We found that higher early postprandial glucagon turnover is the cause of higher early postprandial glucagon concentrations in type 1 diabetes Strategies that decrease early post prandial glucagon fluxes could improve postprandial glucose concentrations in type 1 diabetes.
- 20 November 2025
- Published by American Diabetes Association in Diabetes
- Vol. 75 (2) , 256-263
Postprandial Glucagon Metabolism in Healthy and Type 1 Diabetes
Early postprandial glucagon concentrations are higher in type 1 diabetes (T1D) than in individuals with no diabetes (ND). To determine the cause, we infused stable [13C9, 15N1]glucagon before, during, and after a mixed meal in 16 ND and 16 T1D individuals to measure glucagon turnover. In a subcohort of 9 ND and 12 T1D individuals, we estimated [13C9, 15N1]glucagon kinetics during steady state. A linear, single-compartment model described [13C9, 15N1]glucagon kinetics and allowed precise estimation of the volume of distribution (VD) and clearance rate (CL). Model parameters were similar between groups, with the VD of [13C9, 15N1]glucagon at 42.1 ± 3.3 mL/kg, implying that [13C9, 15N1]glucagon distributes in a single compartment and with VD approximating the plasma volume and CL at 10.6 ± 0.9 mL/kg/min. Higher early (0–120 min after meal ingestion) postprandial glucagon concentrations (1,907.9 ± 373.4 vs. −93.6 ± 240.5 pg/mL · 120 min P < 0.001) observed in T1D was due to higher rates of glucagon appearance (3.39 ± 2.8 vs. −3.95 ± 2.0 ng/kg · 120 min, P < 0.04) and disappearance (2.13 ± 2.6 vs. −5.28 ± 2.1 ng/kg · 120 min, P < 0.04) compared with ND. We have determined postprandial glucagon turnover in humans and have demonstrated that changes in postprandial glucagon concentrations in T1D are due to increased rates of glucagon turnover during the early postprandial period. Article Highlights: This study was conducted to determine postprandial glucagon metabolism in people with and without type 1 diabetes. We wanted to determine the cause for higher early postprandial glucagon concentrations in type 1 diabetes. We found that higher early postprandial glucagon turnover is the cause of higher early postprandial glucagon concentrations in type 1 diabetes Strategies that decrease early post prandial glucagon fluxes could improve postprandial glucose concentrations in type 1 diabetes.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (2) , E355-E367
Quantitative estimation of disposition index from postprandial glucose data across the spectrum of glucose tolerance
The advent of continuous glucose monitoring (CGM) in non-insulin-treated individuals raises the possibility of quantifying disposition index (DI), a key metric of β-cell function usually assessed in research settings, in outpatients. A method for DI estimation from postprandial glucose data only (DIG) was developed and validated against a reference. DIG can be used to assess therapy effectiveness and degree of glucose tolerance in non-insulin-treated individuals, paving the way for its quantification in real-life conditions from CGM devices.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (2) , E355-E367
Quantitative estimation of disposition index from postprandial glucose data across the spectrum of glucose tolerance
The advent of continuous glucose monitoring (CGM) in non-insulin-treated individuals raises the possibility of quantifying disposition index (DI), a key metric of β-cell function usually assessed in research settings, in outpatients. A method for DI estimation from postprandial glucose data only (DIG) was developed and validated against a reference. DIG can be used to assess therapy effectiveness and degree of glucose tolerance in non-insulin-treated individuals, paving the way for its quantification in real-life conditions from CGM devices.
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (1) , E102-E116
Modeling hepatic glucose tracer kinetics from isotope dilution technique and deuterium metabolic imaging in postbariatric surgery and nonoperated individuals
The proposed hepatic model allows, for the first time, to describe postprandial liver glucose tracer kinetics in humans, allowing to estimate exogenous glucose appearance and disposal in the liver, as well as glucose transport and hepatic blood flow rate. The model may become a useful tool in clinical research by supporting the identification of metabolic defects at the hepatic level without requiring invasive procedures.
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (1) , E102-E116
Modeling hepatic glucose tracer kinetics from isotope dilution technique and deuterium metabolic imaging in postbariatric surgery and nonoperated individuals
The proposed hepatic model allows, for the first time, to describe postprandial liver glucose tracer kinetics in humans, allowing to estimate exogenous glucose appearance and disposal in the liver, as well as glucose transport and hepatic blood flow rate. The model may become a useful tool in clinical research by supporting the identification of metabolic defects at the hepatic level without requiring invasive procedures.
- 30 May 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (8) , 1342-1354
Splanchnic and Leg Glucagon Metabolism in Healthy Individuals and Those With Type 1 Diabetes: First-in-Human Study Using [13C9,15N1]Glucagon
Circulating glucagon concentrations differ between individuals with no diabetes (ND) and those with type 1 diabetes (T1D). We combined an isotope dilution technique using stable tracers [6,22-13C9,15N1]glucagon and [6,14,19,22-13C9,15N1]glucagon with splanchnic and leg catheterization in participants with ND (n = 8; age 23.1 ± 2.9 years, BMI 26.6 ± 3.5 kg/m2, HbA1c 5.0 ± 0.2% [31 ± 2 mmol/mol]) and T1D (n = 6; 29.0 ± 8.8 years, BMI 26.3 ± 5.0 kg/m2, HbA1c 7.9 ± 0.8% [63 ± 8 mmol/mol]) in the overnight fasted state. After baseline period, exogenous glucagon was infused at rates designed to achieve plasma glucagon concentrations spanning the physiological ranges, to determine the effects of rising glucagon concentrations on splanchnic and leg glucagon balance. At baseline, splanchnic glucagon extraction (SGE) was similar (30.7 ± 2.7 vs. 29.1 ± 2.9%) but leg glucagon extraction (LGE) was lower (27.0 ± 4.2 vs. 40.6 ± 3.1%) in participants with T1D versus those with ND. However, with increasing plasma glucagon concentrations, while SGE remained unchanged within and between groups, LGE fell in participants with ND (41 vs. 31 vs. 24%) but did not change in those with T1D. Despite a numerically lower net splanchnic glucagon production in participants with T1D than in those with ND, no changes were observed with increasing glucagon concentrations within the physiological range in both groups. This is the first human study applying novel glucagon isotopes that describes regional glucagon metabolism in participants with ND and T1D. Our observations provide translational relevance for dual hormone closed-loop systems and provide tools for probing the effects of GLP-1, dual, and triple receptor agonists on pancreatic α-cell functions. Article Highlights: This study was conducted to assess splanchnic and leg glucagon metabolism in humans using stable glucagon isotopes. We wanted to evaluate whether splanchnic and leg glucagon metabolism differed between participants with no diabetes (ND) and those with type 1 diabetes (T1D) at glucagon concentrations spanning the physiological range. Whereas splanchnic glucagon extraction did not differ between participants with ND and those with T1D, leg glucagon extraction fell in those with ND but did not change in those with T1D as glucagon concentrations increased. Net splanchnic glucagon production did not change with exogenous glucagon infusion. Our study has implications for dual hormone closed-loop control in T1D where glucagon is infused for prevention of hypoglycemia and for investigating the effects of emerging GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists on endogenous glucagon secretion and clearance.
- 30 May 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (8) , 1342-1354
Splanchnic and Leg Glucagon Metabolism in Healthy Individuals and Those With Type 1 Diabetes: First-in-Human Study Using [13C9,15N1]Glucagon
Circulating glucagon concentrations differ between individuals with no diabetes (ND) and those with type 1 diabetes (T1D). We combined an isotope dilution technique using stable tracers [6,22-13C9,15N1]glucagon and [6,14,19,22-13C9,15N1]glucagon with splanchnic and leg catheterization in participants with ND (n = 8; age 23.1 ± 2.9 years, BMI 26.6 ± 3.5 kg/m2, HbA1c 5.0 ± 0.2% [31 ± 2 mmol/mol]) and T1D (n = 6; 29.0 ± 8.8 years, BMI 26.3 ± 5.0 kg/m2, HbA1c 7.9 ± 0.8% [63 ± 8 mmol/mol]) in the overnight fasted state. After baseline period, exogenous glucagon was infused at rates designed to achieve plasma glucagon concentrations spanning the physiological ranges, to determine the effects of rising glucagon concentrations on splanchnic and leg glucagon balance. At baseline, splanchnic glucagon extraction (SGE) was similar (30.7 ± 2.7 vs. 29.1 ± 2.9%) but leg glucagon extraction (LGE) was lower (27.0 ± 4.2 vs. 40.6 ± 3.1%) in participants with T1D versus those with ND. However, with increasing plasma glucagon concentrations, while SGE remained unchanged within and between groups, LGE fell in participants with ND (41 vs. 31 vs. 24%) but did not change in those with T1D. Despite a numerically lower net splanchnic glucagon production in participants with T1D than in those with ND, no changes were observed with increasing glucagon concentrations within the physiological range in both groups. This is the first human study applying novel glucagon isotopes that describes regional glucagon metabolism in participants with ND and T1D. Our observations provide translational relevance for dual hormone closed-loop systems and provide tools for probing the effects of GLP-1, dual, and triple receptor agonists on pancreatic α-cell functions. Article Highlights: This study was conducted to assess splanchnic and leg glucagon metabolism in humans using stable glucagon isotopes. We wanted to evaluate whether splanchnic and leg glucagon metabolism differed between participants with no diabetes (ND) and those with type 1 diabetes (T1D) at glucagon concentrations spanning the physiological range. Whereas splanchnic glucagon extraction did not differ between participants with ND and those with T1D, leg glucagon extraction fell in those with ND but did not change in those with T1D as glucagon concentrations increased. Net splanchnic glucagon production did not change with exogenous glucagon infusion. Our study has implications for dual hormone closed-loop control in T1D where glucagon is infused for prevention of hypoglycemia and for investigating the effects of emerging GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists on endogenous glucagon secretion and clearance.
- Open Access
- 8 November 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (1) , 57-65
Exogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: A randomized clinical trial
- 8 November 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (1) , 57-65
Open AccessExogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: A randomized clinical trial
- Open Access
- 14 October 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (1) , 196-206
In vivo mapping of postprandial hepatic glucose metabolism using dynamic magnetic resonance spectroscopy combined with stable isotope flux analysis in Roux‐en‐Y gastric bypass adults and non‐operated controls: A case–control study
Aims: Roux‐en‐Y gastric bypass (RYGB) surgery alters postprandial glucose profiles, causing post‐bariatric hypoglycaemia (PBH) in some individuals. Due to the liver's central role in glucose homeostasis, hepatic glucose handling might differ in RYGB‐operated patients with PBH compared to non‐operated healthy controls (HC). Materials and Methods: We enrolled RYGB‐operated adults with PBH and HCs ( n = 10 each). Participants ingested 60 g of [6,6′‐ 2 H 2 ]‐glucose ( d ‐glucose) after an overnight fast. Deuterium metabolic imaging (DMI) with interleaved 13 C magnetic resonance spectroscopy was performed before and until 150 min post‐ d ‐glucose intake, with frequent blood sampling to quantify glucose enrichment and gluco‐regulatory hormones until 180 min. Glucose fluxes were assessed by mathematical modelling. Outcome trajectories were described using generalized additive models. Results: In RYGB subjects, the hepatic d ‐glucose signal increased early, followed by a decrease, whereas HCs exhibited a gradual increase and consecutive stabilization. Postprandial hepatic glycogen accumulation and the suppression of endogenous glucose production were lower in RYGB patients than in HCs, despite higher insulin exposure, indicating lower hepatic insulin sensitivity. The systemic rate of ingested d ‐glucose was faster in RYGB, leading to a higher, earlier plasma glucose peak and increased insulin secretion. Postprandial glucose disposal increased in RYGB patients, without between‐group differences in peripheral insulin sensitivity. Conclusions: Exploiting DMI with stable isotope flux analysis, we observed distinct postprandial hepatic glucose trajectories and parameters of glucose–insulin homeostasis in RYGB patients with PBH versus HCs. Despite altered postprandial glucose kinetics and higher insulin exposure, there was no evidence of impaired hepatic glucose uptake or output predisposing to PBH in RYGB patients.
- 14 October 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (1) , 196-206
Open AccessIn vivo mapping of postprandial hepatic glucose metabolism using dynamic magnetic resonance spectroscopy combined with stable isotope flux analysis in Roux‐en‐Y gastric bypass adults and non‐operated controls: A case–control study
Aims: Roux‐en‐Y gastric bypass (RYGB) surgery alters postprandial glucose profiles, causing post‐bariatric hypoglycaemia (PBH) in some individuals. Due to the liver's central role in glucose homeostasis, hepatic glucose handling might differ in RYGB‐operated patients with PBH compared to non‐operated healthy controls (HC). Materials and Methods: We enrolled RYGB‐operated adults with PBH and HCs ( n = 10 each). Participants ingested 60 g of [6,6′‐ 2 H 2 ]‐glucose ( d ‐glucose) after an overnight fast. Deuterium metabolic imaging (DMI) with interleaved 13 C magnetic resonance spectroscopy was performed before and until 150 min post‐ d ‐glucose intake, with frequent blood sampling to quantify glucose enrichment and gluco‐regulatory hormones until 180 min. Glucose fluxes were assessed by mathematical modelling. Outcome trajectories were described using generalized additive models. Results: In RYGB subjects, the hepatic d ‐glucose signal increased early, followed by a decrease, whereas HCs exhibited a gradual increase and consecutive stabilization. Postprandial hepatic glycogen accumulation and the suppression of endogenous glucose production were lower in RYGB patients than in HCs, despite higher insulin exposure, indicating lower hepatic insulin sensitivity. The systemic rate of ingested d ‐glucose was faster in RYGB, leading to a higher, earlier plasma glucose peak and increased insulin secretion. Postprandial glucose disposal increased in RYGB patients, without between‐group differences in peripheral insulin sensitivity. Conclusions: Exploiting DMI with stable isotope flux analysis, we observed distinct postprandial hepatic glucose trajectories and parameters of glucose–insulin homeostasis in RYGB patients with PBH versus HCs. Despite altered postprandial glucose kinetics and higher insulin exposure, there was no evidence of impaired hepatic glucose uptake or output predisposing to PBH in RYGB patients.